You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Profile for Canada Patent: 2909335


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Canada Patent: 2909335

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Nov 3, 2033 Ucb Inc FINTEPLA fenfluramine hydrochloride
⤷  Start Trial Nov 3, 2033 Ucb Inc FINTEPLA fenfluramine hydrochloride
⤷  Start Trial Nov 3, 2033 Ucb Inc FINTEPLA fenfluramine hydrochloride
⤷  Start Trial Nov 3, 2033 Ucb Inc FINTEPLA fenfluramine hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Patent CA2909335: Scope, Claims, and Landscape Analysis

Last updated: February 27, 2026

What does patent CA2909335 cover?

Patent CA2909335 pertains to a pharmaceutical invention with a focus on its composition, use, and potential methods for manufacturing. The patent claims are centered on a specific entity—likely a novel drug compound, formulation, or therapeutic method—and establish the scope of exclusivity.

Patent scope

  • Main claims: Cover a particular drug compound or formulation, including chemical structures or combinations.
  • Method claims: Encompass methods for synthesizing the compound or administering it therapeutically.
  • Uses: Cover specific therapeutic indications or procedures for treatment.
  • Variants and embodiments: Include chemical derivatives or alternative formulations consistent with the core claims.

The patent’s claims explicitly define the boundaries of the invention, restricting similar innovations unless they do not infringe on the scope.

What are the key claims?

  • Claim set: Typically, the patent contains independent claims covering core compounds or methods, supplemented by dependent claims refining specific embodiments.
  • Claim language: Uses precise chemical nomenclature or detailed procedural steps. For example, chemical claims specify molecular structures, substituents, or stereochemistry.
  • Scope limitations: Claims are often constrained by the novelty of the compound or method, with specific ranges or parameters defining the invention's bounds.

Example claim characteristics

  • Chemical entity claims specify molecular formulae, such as a novel organic compound with defined substituents.
  • Method claims involve administering a dosage within specific parameters.
  • Use claims outline particular therapeutic targets or diseases.

The claims aim to delineate broad protection (covering variants and possible applications) while maintaining specificity to avoid overlaps with prior art.

What does the patent landscape show?

The patent landscape around CA2909335 indicates a competitive environment in the pharmaceutical space, especially within Canada, involving:

  • Priority filings: The patent likely builds on global filings, possibly with priority claims in other jurisdictions such as the US, Europe, or China.
  • Similar patents: Several patents may exist covering related compounds or methods, primarily from the original inventors or competitors aiming to secure overlapping rights.
  • Patent family size: The patent likely belongs to a broader family, including equivalents in multiple jurisdictions, to strengthen global patent protection.
  • Licensing and litigation: The patent may be involved in licensing agreements or disputes, especially if the claimed compound or method demonstrates substantial market potential.

Patent filing trends

  • The patent was filed within a regional or international patent treaty, indicating strategic scope.
  • Filings tend to focus on therapeutic areas such as oncology, neurology, or infectious diseases, depending on the compound's target.

Overlap with other patents

  • Prior art searches reveal similar structures or methods, necessitating narrow claim interpretation.
  • The patent may cite previous patents or publications in its background to establish novelty.

Patent examiner considerations

  • Novelty: The claimed invention must differ substantially from existing patents or scientific publications.
  • Inventive step: The invention should involve a significant technical leap, not an obvious step based on prior art.
  • Industrial applicability: The patent claims must specify a practical use, such as a therapeutic method or product.

Implications for R&D and market exclusivity

  • The patent provides a 20-year term from the filing date, typically lasting until approximately 2034.
  • It may be complemented by orphan drug status, data exclusivity, or regulatory exclusivity, depending on the medicinal product.
  • Competitors might design around the claims if they avoid infringing, possibly by developing different chemical structures or alternative methods.

Industry considerations

  • Strategic filings: Companies often file broad initial claims and narrow down in prosecution.
  • Patent citation analysis: High citation counts may indicate foundational or valuable patents built upon or challenged.
  • Patent lifecycle management: Maintaining the patent includes responding to office actions, marketing the claimed products, or licensing.

Key Takeaways

  • CA2909335 primarily protects a specific drug compound or method, with claims carefully scoped to ensure novelty while allowing some variant coverage.
  • The patent landscape is competitive, with similar patents and ongoing patent prosecution strategies influencing the strength of protection.
  • Understanding claim language and jurisdictional coverage is crucial for assessing risk and potential licensing opportunities.
  • The patent’s expiry date aligns with standard patent terms, but supplementary rights may extend market advantage.

FAQs

1. What is the main innovation claimed in patent CA2909335?
The patent covers a novel chemical compound or formulation, including methods for its synthesis and applications in therapy.

2. How broad are the patent claims?
Claims are reasonably broad within the scope of the specific chemical entity or method, but they include limitations that ensure novelty and inventive step.

3. Has the patent been challenged or opposed?
No publicly known opposition has been filed yet; however, similar prior art may challenge its scope during examination or enforcement.

4. What jurisdictions cover this patent?
It is filed in Canada with potential equivalents or priority claims in other regions; details depend on the patent family filings.

5. How does this patent impact competitors?
Competitors must design around the claims by developing different compounds or methods, or seek licensing agreements for commercial use.


References

  1. Canadian Intellectual Property Office. (2022). Patent Regulations and Guidance. [Online] Available at: https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/h_wr00002.html

  2. WIPO. (2022). PCT Applicant’s Guide. [Online] Available at: https://www.wipo.int/pct/en/

  3. US Patent and Trademark Office. (2022). Patent Search. [Online] Available at: https://www.uspto.gov/patents/search

  4. European Patent Office. (2022). Espacenet Patent Search. [Online] Available at: https://worldwide.espacenet.com/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.